Recurrence after radical prostatectomy for organ-confined prostate cancer

Onkologie

Volumn 26, Issue 4, 2003, Pages 330-333

  Scheepe, J R ^a   Vis, A N ^a   Mickisch, Gerald H ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Center of Operative Urology Bremen   (Germany)

Author keywords

Prognosis; Progression; Prostate cancer; PSA; Surgical margins

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER PATIENT; CANCER RECURRENCE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISSECTION; FOLLOW UP; HUMAN; IMAGING; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATIENT CODING; PATIENT SELECTION; PELVIS LYMPH NODE; PREOPERATIVE PERIOD; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECURRENT CANCER;

ADULT; AGED; BIOPSY; DISEASE-FREE SURVIVAL; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141676499     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072090     Document Type: Article

References (13)

1. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
2. Takayama T, Krieger JN, True LD: Recurrent prostate cancer despite undetectable prostate specific antigen. J Urol 1992;148:1541-1542.
3. Stein A, Dekernion JB, Smith RB, Dorey F, Patel H: Prostate specific antigen levels after radical prostatectomy in patients with organ-confined and locally extensive prostate cancer. J Urol 1992;147:942-946.
4. Zincke H, Oesterling JE, Glute ML, Bergstralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
5. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994;152:1843-1849.
6. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-1830.
7. Mickisch GH, Kranse R, Verkerk A, Hoedemaker R, Schroeder F: Biochemical progression after surgically radical resection for pT2 prostate cancer. J Urol 1998;159:217.
8. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy. The John Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
9. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152:1837-1842.
10. Epstein JI, Partin AW, Sauvageot J, Walsh PC: Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-292.
11. Lerner SE, Blute ML, Bergstralh EJ, Bostwick DG, Eickholt JT, Zincke H: Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol 1996;156:137-143.
12. van Brussel JP, van Steenbrugge GJ, van Krimpen C, Bogdanowicz JFAT, van der Kwast TH, Schroeder FH, Mickisch GHJ: Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer. J Urol 2001;165:130-135.
13. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vesella R: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873-879.